Osphos® (clodronate injection)
by Dechra Veterinary- Injectable bisphosphonate
- Indicated for the control of clinical signs associated with navicular syndrome
- Only bisphosphonate approved by FDA
| Catalog # | Description | Price | Qty | Autoship | CART | FAVORITES |
sc-516037Rx | 60 mg/ml, 15 ml | $399.00 |
Click product's Autoship icon - choose frequency at Checkout.
Never forget a shipment so you're always stocked.
Saves you 5% on UltraCruz® products.
You manage the frequency or cancellation to fit your needs.
OSPHOS is an injectable bisphosphonate indicated for the control of clinical signs associated with navicular syndrome in horses 4 years and older. OSPHOS is the only bisphosphonate approved by FDA for intramuscular use in horses.
Clodronate, the active ingredient in OSPHOS, is a bisphosphonate that in laboratory animal studies and in vitro studies is known to inhibit bone resorption by reducing the number of active osteoclasts, regardless of the cause of osteoclast activity and it inhibits the formation and dissolution of calcium phosphate crystals in the bone matrix.
Osphos® (clodronate injection) 60 mg/ml is for intramuscular use in horses for the control of clinical signs associated with navicular syndrome in horses. Supplied as 15 ml vial.
